In the pipeline from Derek Lowe – Page 11
-
Opinion
Divided by a common language
Derek Lowe dreams of the day when chemists and biologists can understand each other
-
Opinion
A dose of realism
The recent row over antidepressants reminds us how little we know about the brain, says Derek Lowe
-
Opinion
A notable year for closures and layoffs
It's been a rough year, but the future looks bright, says Derek Lowe
-
Opinion
The hidden benefit of higher energy bills
The high cost of energy has an unexpected benefit, says Derek Lowe - it forces us to be more efficient
-
Opinion
Zero justification
Will Phase Zero trials actually help drug development, wonders Derek Lowe
-
Opinion
Credit where it's due
Process chemists just don't get the credit they deserve, says Derek Lowe
-
Opinion
Blinkers for bad news
The Avandia controversy poses some tough questions about how to balance risks, says Derek Lowe
-
Opinion
Patented fundamentals
Derek Lowe sets the record straight about pharmaceutical patents on traditional medicines
-
Opinion
Reasons to be cheerful
After months of bleak news about faltering pipelines and redundancies, it's time to find reasons to be cheerful about the drug industry, says Derek Lowe.
-
Opinion
Justifying total synthesis
Derek Lowe wonders whether total synthesis is still worth the effort
-
Opinion
Mergers: a cost-benefit analysis
Do the benefits of pharmaceutical company mergers really outweigh the costs, asks Derek Lowe
-
Opinion
Science's secret recipe
Derek Lowe wonders whether the secret recipe for scientific breakthroughs can be taught – and how much indigestion that recipe would cause in the boardroom
-
Opinion
Learning from pharma failures
Derek Lowe looks at the recent failure of Pfizer's cholesterol drug, torcetrapib, and asks what it means for the future of pharmaceutical research
-
Opinion
Global pharma investment
Derek Lowe looks at the story behind the growing investment by western companies in medicinal chemistry research in China
-
Opinion
Time to let go
Derek Lowe wonders how to kill off bad drug candidates before companies invest valuable time and money in them